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How to evaluate performance of prediction
methods? Measures and their interpretation in
variation effect analysis
Mauno Vihinen1,2,3
From SNP-SIG 2011: Identification and annotation of SNPs in the context of structure, function and disease
Vienna, Austria. 15 July 2011
Abstract
Background: Prediction methods are increasingly used in biosciences to forecast diverse features and
characteristics. Binary two-state classifiers are the most common applications. They are usually based on machine
learning approaches. For the end user it is often problematic to evaluate the true performance and applicability of
computational tools as some knowledge about computer science and statistics would be needed.
Results: Instructions are given on how to interpret and compare method evaluation results. For systematic method
performance analysis is needed established benchmark datasets which contain cases with known outcome, and
suitable evaluation measures. The criteria for benchmark datasets are discussed along with their implementation in
VariBench, benchmark database for variations. There is no single measure that alone could describe all the aspects
of method performance. Predictions of genetic variation effects on DNA, RNA and protein level are important as
information about variants can be produced much faster than their disease relevance can be experimentally
verified. Therefore numerous prediction tools have been developed, however, systematic analyses of their
performance and comparison have just started to emerge.
Conclusions: The end users of prediction tools should be able to understand how evaluation is done and how to
interpret the results. Six main performance evaluation measures are introduced. These include sensitivity, specificity,
positive predictive value, negative predictive value, accuracy and Matthews correlation coefficient. Together with
receiver operating characteristics (ROC) analysis they provide a good picture about the performance of methods
and allow their objective and quantitative comparison. A checklist of items to look at is provided. Comparisons of
methods for missense variant tolerance, protein stability changes due to amino acid substitutions, and effects of
variations on mRNA splicing are presented.
Background
Gene and genome sequencing speed is ever increasing
and thus lots of genetic variation information is available.
The technological development of sequencing methods
has led to a situation where the interpretation of the gen-
erated data is a severe bottleneck for the use of genetic
information. Numerous prediction methods have been
developed during the last decade to address the relevance
of gene and protein variants to pathogenicity. General
tolerance methods predict whether the variants are dis-
ease-related or not (or affect protein function or not),
and specific methods are used to address variation effect
mechanisms [1]. These methods can be useful. However,
until recently their true applicability and performance
have not been studied systematically [2-5]. When meth-
ods are originally published, authors provide some
performance measures, which are usually not comparable
with other methods due to the use of different training
and test datasets, different reported measures etc. The
scope of this article is to discuss how the assessment of
method performance should be done and interpretation
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of the results and the choice of the best methods. The
text is mainly intended for scientists who are users of
predictors without training in statistics or computer
science. Method developers are taken into account by
providing a checklist of items to be reported with meth-
ods. The examples discussed are related to prediction of
variant effects, but description of methods and evaluation
measures is general and thereby not application domain
specific.
Method testing schemes
Three approaches can be used for testing method per-
formance and can be classified according to increasing
reliability (Fig. 1).
Challenges aim to test whether certain problems can be
addressed with existing tools and to find out what kind of
methods will be needed in the future. Critical Assessment
of Structure Predictions (CASP) [6] was the first chal-
lenge of this kind in biosciences. The idea was, and still
is, even when CASP has been running for 20 years, to
test how prediction methods behave on different protein
structure related tasks. The method developers apply
their systems without knowing the correct result (blind
test), which however is available for the challenge asses-
sors. This setup allows independent testing of method
performance. In a similar vein, other critical assessment
challenges have been organized e.g. for Critical Assess-
ment of protein Function Annotation (CAFA) [7] and
Critical Assessment of PRediction of Interactions
(CAPRI) [8].
CAGI, Critical Assessment of Genome Interpretation
(http://genomeinterpretation.org/), is a challenge for
method developers in the field of phenotypic impacts of
genomic variation. The second CAGI prediction season
was organized during fall 2011. These challenges do not
aim for systematic analysis of predictions, instead they
assess what is currently doable, providing proof of con-
cept, charting where to direct future efforts, and identi-
fying new areas where predictive approaches would be
needed.
The second test strategy is typically used by method
developers to test their approaches. These are usually
done with developer collected test sets (especially when
benchmark datasets are lacking) and report certain per-
formance parameters. Most often the testing is not com-
prehensive, and the results are incomparable with those
obtained from other methods e.g. due to using different
test sets. Sometimes evaluation parameters are selectively
presented which leads to problems in determining the
true merits and pitfalls of methods.
The third approach, systematic analysis, uses approved
and widely accepted benchmark dataset(s) and suitable
evaluation measures to explain method performance. It is
hoped that in the future the variation effect program
developers would use benchmark test sets and compar-
able measures. This is already the general practice e.g. in
the multiple sequence alignment (MSA) field.
Prediction methods for classification
A plethora of pattern recognition methods have been
applied to problems in bioinformatics including rule
based, statistical methods and machine learning -based
methodologies. The goal of machine learning is to train a
computer system to distinguish i.e. classify cases based on
known examples. Machine learning methods include sev-
eral widely differing approaches such as support vector
machines, neural networks, Bayesian classifiers, random
forests and decision trees.
In the following discussion we concentrate on machine
learning methods as they are nowadays widely used to
tackle complex phenomena, which would be otherwise
difficult to handle. Successful machine learning method
development requires good quality training set. The data-
set should represent the space of possible cases. This
space is huge for genetic variations as they can have so
many different effects and underlying mechanisms.
Another aspect is the choice of the machine learning
approach. There is not a superior architecture among
them. Third, the quality of the predictor depends on how
the training has been done, which features are used to
Figure 1 Method performance analysis schemes The performance of the computational methods can be addressed with three different
approaches which yield different reliability for the assessment.
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explain the phenomenon and optimization of the
method.
Fig. 2 depicts the principle underlying machine learning
in a two-class classification task. The predictor is trained
with known positive and negative instances in an approach
called supervised learning. This leads to reorganization of
the system, details of which differ according to the architec-
ture employed. Once the method has learned to distinguish
between the cases it can be applied to predict the class of
unknown cases. The predictors can be classified as discrete
or probabilistic depending on whether they provide a score,
not necessarily a p value, for predictions. In the case of
methods with discrete output, more or less ad hoc thresh-
olds have been used to detect the most reliable events.
Many machine learning based predictors are binary classi-
fiers, however, it is possible to have more than two outputs
e.g. by using multi-tier two-class prediction system.
Features describe the characteristics of the investigated
phenomenon. If several features are available it is impor-
tant to choose those, which best capture the phenomenon.
This is partly due to the curse of dimensionality, which
means that much more data are needed when the number
of features increases. The volume of the feature space
grows exponentially with the dimensionality such that the
data become sparse and insufficient to adequately describe
the pattern in the feature space. Another problem is over-
fitting, which means that the learner, due to sparse data,
complex model or excessive learning procedure, describes
noise or random features in the training dataset, instead of
the real phenomenon. It is crucial to avoid overfitting as it
leads to decreased performance on real cases.
Many predictors provide a measure for the probability of
prediction, in this domain a measure of how likely the var-
iation is pathogenic. This information can be used for
ranking the investigated cases. A more advanced version is
to obtain e.g. by bootstrapping an estimate of the standard
error of the prediction indicative of the prediction
reliability.
Many types of biological data are limited in quantity.
The same data cannot be used both for method training
and testing. The trick is to partition the dataset. This can
be done in different ways, with cross-validation probably
being the most popular of these. The dataset is divided
into k disjoint partitions, one of which is used for testing
and the others for training. This is repeated k times until
all the partitions have been used as test set. Ten parti-
tions i.e. ten times cross validation is the most common
partitioning scheme. The average performance measures
computed from the splits are used to describe the overall
prediction performance. Random sampling is another
approach, however, a problem is that the same cases may
appear more than once in the test set and others not at
all. Another computationally intensive validation
approach is leave one out validation, an extreme case of
cross validation with partitioning to the total number of
instances. As the name implies, one case at time is left
for validation while the remaining cases are used for
training. The computational requirements may be prohi-
bitive with large datasets. A problem especially for the
last scheme is if there are some very similar cases in the
dataset.
Typically the training set should contain about equal
amount of cases in each class. Imbalance in the numbers
of cases in the classes can cause problems during perfor-
mance evaluation as discussed below. There are some
ways to handle class imbalance.
Principles of method evaluation
To test and compare predictors two requirements have
to be met. There has to be available test dataset with
known outcome and there has to be in place suitable pre-
diction performance evaluation measures. Benchmark is
a gold standard dataset - cases with experimentally vali-
dated known effects which represent the real world.
These can be used for training machine learning methods
as well as for testing the developed methods. The same
Figure 2 Principles of machine learning Machine learning is a form of supervised learning in which a computer system learns from given
positive and negative instances to distinguish between cases belonging to the two classes. During training, positive and negative cases (black
and white balls) are provided for the system, which leads to organization of the predictor (indicate by the arrangement of the black and white
squares inside the predictor) such that it learns to separate the cases and thus can classify unknown cases (balls with question marks).
Depending on the classifier, whether it yields in addition to the classification also a score for the prediction, the results can be called as discrete
or probabilistic.
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data should however never be used for training and test-
ing as that would only indicate the capacity of the
method to memorize examples, not its generalization
potential – how well it performs on instances outside the
training set. High quality benchmark datasets require
meticulous data collection often from diverse sources
and careful checking of the correctness of the data.
Numerous measures have been developed to describe
predictor performance, but no single measure captures all
aspects of predictor performance. The measures mainly
used, and how to interpret them will be discussed. Typi-
cally prediction methods are used as classifiers to define
whether a case has the investigated feature or not. Results
of this kind of binary predictor can be presented in a 2x2
confusion table also called contingency table or matrix.
This, at first glance may appear simple to interpret, but
the contrary is the case, as various composite aspects have
to be jointly taken into account.
Benchmark criteria
Benchmark can be defined as a standard or reference for
evaluation, in this case prediction method performance.
Benchmarks are widely used in computer science and
technology. For example computer processor performance
is tested with standardized benchmark methods. In bioin-
formatics there are benchmarks e.g. for multiple sequence
alignment methods already 1990’s [9]. Novel MSA con-
struction methods are routinely tested with alignment
benchmarks such as BAliBASE [10] HOMSTRAD [11],
OxBench suite [12], PREFAB [13], and SABmark [14] .
Other bioinformatic benchmarks include protein 3D
structure prediction [15-17], protein structure and func-
tion prediction [18], protein-protein docking [19] and
gene expression analysis [20,21] benchmarks etc.
Benchmark usage varies between different communities.
For variation effect predictions, benchmarks have not been
available and thus authors have used different datasets.
The situation has changed only recently with the release
of VariBench (http://bioinf.uta.fi/VariBench/) (Nair and
Vihinen, submitted).
To be useful a benchmark should fulfill certain criteria.
These criteria vary somewhat between the domains, but
there are also some common features (Fig. 3). The criteria
laid by Gray originally for database systems and transac-
tion processing systems are still valid [22]. Criteria for
MSA [23] and variation data (Nair and Vihinen, sub-
mitted) benchmarks have been defined. These include
relevance, which means that the data have to capture the
characteristics of the problem domain. Portability allows
testing of different systems. Scaleability of the benchmark
allows testing systems of different sizes, and simplicity
means that the benchmark has to be understandable and
thereby credible. Accessibility means that the benchmark
has to be publicly available, solvability to set the level of
the task on suitable level (not too difficult, not hoo hard),
independence to guarantee that the benchmark has not
Figure 3 Benchmark criteria Criteria for benchmarks in three different studies. VariBench is the database specifically designed for variation
benchmark datasets.
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been developed with tools to be tested, and evolution to
keep the benchmark up-to-date during time.
When considering the variation benchmarks, datasets
should be large enough to cover variations related to a cer-
tain feature or mechanism. For example in the case of mis-
sense variations this means very large numbers of
instances as there are altogether 150 single nucleotide
changes which cause amino acid substitution. To have sta-
tistical power several cases are needed. The required num-
bers of cases increase exponentially as features are
combined. Datasets have to be non-redundant and devoid
of similar or greatly overlapping entries. This criterion
relates to independence requirement of [23]. Datasets have
to contain both positive (showing the investigated feature)
and negative (not having effect) cases so that the capability
of methods to distinguish effects can be tested. This may
cause problems in data collection as some phenomena are
very rare and only a few known cases may exist.
VariBench is a database for variation-related benchmark
datasets that can be used for developing, optimizing, com-
paring and evaluating the performance of computational
tools that predict the effects of variations (Nair and Vihi-
nen, submitted). VariBench datasets provide multilevel
mapping of the variation position to DNA, RNA and pro-
tein as well as to protein structure entries in PDB [24]
(when possible). Method developers are requested to sub-
mit their datasets to VariBench to be distributed to the
community.
VariBench datasets have been collected from literature
as well as with data mining approaches from diverse
sources. Locus specific databases (LSDBs) are the most
reliable source for disease-related data. Although lots of
variation data are listed in LSDBs, it would be necessary to
capture to databases all the cases from clinical and
research laboratories [25,26].
An integral part of databases is the annotation of the
entries. For variation information collection it would be
extremely important to describe the cases in a systema-
tic and unambiguous way.
Variation Ontology (VariO, http://variationontology.org/
) has been developed for systematic description and anno-
tation of variation effects and consequences on DNA,
RNA and/or protein including variation type, structure,
function, interactions, properties and other features (Vihi-
nen, in preparation). VariO annotated data would allow
easy collection of novel dedicated benchmarks.
Evaluation measures
The outcome of binary (pathogenic/benign) style predic-
tors are often presented in a 2x2 contingency table (Fig. 4).
The number of correctly predicted pathogenic (non-
functional) and neutral (functional) cases are indicated by
TP (true positives) and TN (true negatives), and the num-
ber of incorrectly predicted pathogenic and neutral cases
are FN (false negatives) and FP (false positives),
respectively.
The goal of two-class prediction methods is to separate
positive cases from negative ones. Because the predictions
for the two classes usually overlap a cut off distinguishing
the categories has to be optimized (Fig. 5). By moving the
cut off different amounts of misclassified cases FN and FP
appear. By using well behaved representative data and well
trained classifier the misclassifications can be minimized.
Figure 4 Contingency matrix and measures calculated based
on it 2x2 contigency table for displaying the outcome of
predictions. Based on the table it is possible to calculate row and
column wise parameters, PPV and NVP, and sensitivity and
specificity, respectively. These parameters are useful, but are not
based on all the information in the table. Accuracy is a measure
that is calculated based on all the four figures in the table.
Figure 5 Separation of classes In most classification problems the
two classes are overlapping. By moving the cut off position the
amount of the overlap of the classes can be adjusted. FN and FP
are misclassified cases. The prediction methods aim at optimizing
the cut off and thereby adjusting the numbers in the contingency
table.
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Based on the four descriptors several further measures
can be calculated (Fig. 4). Sensitivity, also called true posi-
tive rate (TPR) or recall, and specificity (true negative rate,
TNR) show the ratio of the pathogenic and neutral cases
correctly identified by the programs. Positive predictive
value (PPV) (also called precision) and negative predictive
value (NPV) is the conditional probability that a patho-
genic or neutral variant is predicted as pathogenic or neu-
tral, respectively. The mathematical basis of these and
other parameters have been discussed in detail [27].
A single parameter cannot capture all the information of
the contingency matrix. Unless representative numbers of
positive and negative cases are used, the values of NPV
and PPV may be biased, even meaningless. The usual
requirement is that the numbers be equal. Sometimes in
literature the datasets are very skewed. Table 1 indicates
the effect of the class imbalance. Results are shown in
addition to equally distributed dataset also for analyses
when there is ± 25 % or ±50 % difference in the total num-
ber of negative and positive cases. In the column wise
parameters, which are for the ratios of either positive or
negative cases (sensitivity and specificity), are not affected
whereas there is a significant difference in NPV and PPV,
which are row wise ratios based on numbers of both posi-
tive and negative cases. In all the examples, 75 % of both
positive and negative cases are correctly predicted and
therefore sensitivity and specificity remain the same. It is
thus apparent that imbalance in class sizes grossly affects
the NPV and PPV evaluation criteria.
To overcome the class imbalance problem different
approaches can be taken. One is to prune the size of the
bigger class to be that of the smaller one. It is also possible
to normalize in the contingency table the values of either
positive or negative cases to have the total of the other
class. Quite often in bioinformatics limited amount of data
are available and therefore one would be reluctant to
delete part of the datasets. When normalizing the data be
sure that the existing dataset is representative otherwise
bias in the set may further be increased.
Accuracy and MCC
Specificity, sensitivity, PPV and NPV are calculated by
using only half of the information in the contingency table
and thus cannot represent all aspects of the performance.
Accuracy (Fig. 4) and Matthews correlation coefficient
(MMC) take benefit of all the four numbers and as such
are more balanced, representative and comprehensive
than the line or column wise measures.
The MCC is calculated as follows:
MCC
TP TN FP FN
TP FN TN FP TP FP TN FN
      ( )( )( )( ) .
For all the measures discussed in here applies that
higher the value the better. Except for MCC, the values
range from 0 to 1. MCC ranges from -1 to 1. -1 indi-
cates perfect negative correlation, 0 random distribution
and 1 perfect correlation. Accuracy and MCC are
affected by class imbalance only in extreme cases.
The effect of the correctly predicted cases on the para-
meters in equally distributed dataset is shown in Fig. 6.
The value for MCC grows slower than the others reach-
ing 0.5 when 75 % of cases are correctly predicted. Ran-
dom results (50 % of both negative and positive correctly
predicted) gives a value of 0, while the other parameters -
sensitivity, specificity, PPV, NPV, and accuracy are 0.5.
Fig. 6. can be used to check the performance of equally
Table 1 Evaluation measures for test data
-50 % -25 % Equal +25 % +50 %
tp 750 750 750 750 750
fn 250 250 250 250 250
tn 375 563 750 938 1125
fp 125 187 250 312 375
sensitivity 0.75 0.75 0.75 0.75 0.75
specificity 0.75 0.75 0.75 0.75 0.75
PPV 0.86 0.80 0.75 0.71 0.67
NPV 0.60 0.69 0.75 0.79 0.82
accuracy 0.75 0.75 0.75 0.75 0.75
MCC 0.48 0.50 0.50 0.50 0.49
Example of a situation when both positive and negative cases have the same
rate of correct predictions (75 %) and when the amount of negative cases is
either equal or 25 or 50 % lower or higher than that for positive cases.
Figure 6 The growth of the performance measures along
increasing reliability Graphs for quality measures for equally
distributed data (same amount positive and negative cases) when
the performance increases equally in both classes. The solid curve
indicates the growth of sensitivity, specificity, PPV, NPV, and
accuracy. The dotted line is for MCC.
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distributed dataset if e.g. some parameters in an article
are not provided. Biases can easily be seen as deviations
from the relationships in the figure. To obtain full picture
of the predictor performance it is important to evaluate
all the six measures together.
Other parameters
Several other parameters can be derived from the contin-
gency matrix. These are not discussed further as they are
not widely used in literature and can be easily calculated
from the six previously presented parameters. These
include false positive rate (FPR) which equals 1-specificity
and false negative rate (FNR) which is 1-sensitivity. False
discovery rate (FDR) is 1-PPV.
Positive and negative likelihood ratios are calculated as
follows:
LR
LR
   
  
sensitivity
specificity
sensitivity
FPR
 and
sensi
1
1 tivity
specificity
FNR
specificity
 .
F measure is another one that uses all the data. It is
calculated as:
F   2
PPV sensitivity
PPV sensitivity
.
Other measures include e.g. Hamming distance and
quadratic distance (also called for Euclidean distance),
which are the same for binary data, and relative entropy
and mutual information [27].
ROC analysis
Receiver operating characteristics (ROC) analysis is a
visualization of prediction performance, that can be used
to select suitable classifier (for review see [28,29]). It indi-
cates the tradeoffs between sensitivity and specificity. ROC
curves can be drawn with specific programs when the pre-
dictor is of probabilistic type and provides a score for the
classification. The score is usually not a real p value, but a
value usable for ranking the predictions.
ROC curve (Fig. 7a) is drawn by first ranking the data
based on the prediction score. Then the data are divided
to intervals of equal size. The upper limit for the partitions
is the number of cases in the dataset. ROC curve has on
x-axis 1-specificity also called FPR and on the y-axis sensi-
tivity (TPR).
Computer program establishes cut offs at intervals,
calculates contingency table for data in the interval, and
determines the values for sensitivity and 1-specificity,
which is plotted to the graph. The procedure is repeated
for each partition. If cross validation has been used,
then the ROC curve can be used to show the average
and variance of the results.
In an ideal case all the true positive cases are on the first
half of the ranked list and the plot rises to (0,1) and then
continues straight to the right with all the true negative
cases. A random classification would be on the diagonal
i.e. mixed correct and wrong cases. The faster the curve
rises and the higher it reaches in the beginning the better
the method is. Methods can be compared with ROC ana-
lysis when the same test dataset (benchmark) is used
(Fig 7b). The curve that runs higher is for a better method.
If the curves cross (Fig 7c) the comparison is no more
meaningful.
Area under the ROC curve (AUC) has been used as a
measure of goodness for predictions (Fig. 7a). It approxi-
mates the probability of ranking a randomly chosen posi-
tive instance higher than a randomly chosen negative one.
A value of 0.5 indicates random and useless classification
while 1 would indicate perfect classifier. Note that AUC
Figure 7 ROC analysis and AUC a) Principle of ROC analysis. b) Comparison of predictors based on the ROC curves when the methods are
tested with the same dataset (benchmark). c) If the curves cross the comparison is no more meaningful.
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can be even smaller than 0.5. One should bear in mind
that the ROC curve does not directly indicate the perfor-
mance of a method. It shows the method’s ranking poten-
tial, which is related to overall performance, further
strengthening the fact that a single measure cannot fully
describe the predictive performance even if it produces a
graph.
What if the data is classified to more than two
classes?
If there are more than two classes the measures described
above cannot be applied. The data can still be presented
in an N x N contingency table. One approach is to divide
the data into several partitions of two categories.
If parameters are needed for all the classes there are
some options available, however, single measures are
more problematic. It is possible to calculate row and col-
umn wise ratios in the same way as in Fig. 4. MCC is in
fact a special case for binary data of linear correlation
coefficient, which can be used for several classes in its
general format. Mutual information analysis can be used
in these cases, as well. Applicable measures have been
discussed e.g. in [27].
Examples of performance comparisons
This section discusses examples of variation effect pre-
diction method evaluations. These include methods for
amino acid substitution (missense variation) tolerance,
point variation effects on protein stability and variations
related to mRNA splicing. The discussion concentrates
on the comparison principles, especially in the light of
the discussion on requirements mentioned above. The
actual comparisons are not presented as it would have
required publication of substantial parts of the reports.
As a single parameter is insufficient for ranking meth-
ods, the readers are directed to the original articles to
find all the details. Here a summary to the methodology
and use of the evaluation parameters is provided.
Protein tolerance predictors
Single nucleotide alterations are the most common genetic
variation type. Human genomes contain these variations
on average at every kilobase. Several computational meth-
ods have been developed to classify these variations [1].
The evaluated methods were MutPred, nsSNPAnalyzer,
Panther, PhD-SNP, PolyPhen, PolyPhen2, SIFT, SNAP,
and SNPs&GO [5]. The methods differ in the properties
of the variant they take into account, as well as in the nat-
ure and the classification method. Panther, PhD-SNP and
SIFT are based on evolutionary information. MutPred,
nsSNPAnalyzer, PolyPhen2, SNAP and SNP&GO combine
protein structural and/or functional parameters and
sequence analysis derived information. Most of these are
based on machine-learning methods.
The positive test dataset included 19,335 missense var-
iations from the PhenCode database [30], IDbases [31]
and from 18 additional LSDBs. The negative dataset con-
sisted of 21,170 nonsynonymous coding SNPs with an
allele frequency >0.01 and chromosome sample count
higher than 49 from the dbSNP database. As large num-
bers of individual predictions were the Pathogenic-or-not
Pipeline (PON-P) [32] was used for the submission of
sequences and variants into the analysed programs.
The performance was evaluated with the six measures
described above. The performances of the programs ran-
ged from poor (MCC 0.19) to reasonably good (MCC
0.65) [5].
It has been widely accepted that information about
protein three dimensional structure would increase pre-
diction performance. The very best methods use also
structural and functional information, whereas others
that are solely based on sequence level information per-
form rather well.
Further analyses were made to compare the methods
pairwise, and to study whether the type of original or sub-
stituting amino acid residue, the structural class of the
protein, or the structural environment of the amino acid
substitution, had an effect on the prediction performance.
Existing programs thus have widely varying perfor-
mance and there is still need for better methods. Con-
sidering all the evaluation measures, no single method
could be rated as best by all of them.
Protein stability predictors
Stability as a fundamental property affects protein func-
tion, activity, and regulation. Changes to stability are
often found to be involved in diseases. Systematic per-
formance evaluation analysis has been made for eleven
stability predictors performances including CUPSAT,
Dmutant, FoldX, I-Mutant2.0, two versions of I-
Mutant3.0 (sequence and structure versions), MultiMu-
tate, MUpro, SCide, Scpred, and SRide [2]. SCide and
Scpred, which predict stability centers, as well as SRide,
which predicts stabilizing residues, predict only destabi-
lizing effects, while all the others evaluate both stabiliz-
ing and destabilizing changes.
The major database for protein stability information is
ProTherm [33]. The pruned dataset for testing con-
tained 1784 variations from 80 proteins, with 1154 posi-
tive cases of which 931 were destabilizing (ΔΔG ≥ 0.5
kcal/mol), 222 were stabilizing (ΔΔG ≤ –0.5 kcal/mol),
and 631 were neutral (0.5 kcal/mol ≥ ΔΔG ≥ –0.5 kcal/
mol). The majority of the methods had been trained
using data from ProTherm, and thus only those cases
that had been added to the database after training had
occurred were used for testing.
Of the measures recommended in here the authors
used four, namely accuracy, specificity, sensitivity, and
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MCC and the remaining row wise parameters could be
calculated from the confusion tables.
There were three groups of data, stability increasing,
neutral and stability decreasing. The authors solved the
problem of multiple classes by presenting three tables of
results. The first one was grouped so that both stability
increasing and decreasing were considered as pathogenic
i.e. positive. In these analyses only two classes were con-
sidered, stabilizing or destabilizing and neutral cases.
The results for the all the cases show that accuracy
ranges from 0.37 to 0.64 and MCC from -0.37 to only
0.12. All the programs succeeded better when predicting
stability increasing or decreasing variations individually.
The MCC reaches 0.35 and 0.38 for the methods best in
predicting stability increasing and decreasing variants,
respectively [2].
Further analyses were made about variations located
in different protein secondary structural elements, on
the surface or in the core of a protein, and according to
protein structure type.
The conclusion was that even at best, the predictions
were only moderately accurate (~60%) and significant
improvements would be needed. The correlation of the
methods was poor.
In another study six programs includeing CC/PBSA,
EGAD, FoldX, I-Mutant2.0, Rosetta, and Hunter were
compared [3]. The dataset contained 2156 single varia-
tions from ProTherm. The goal of the study was to com-
pare the performance of the methods in ΔΔG prediction.
Thus, they did not directly predict the effect on protein
function, just the extent of free energy change. The only
measure used was correlation between the experimental
and predicted ΔΔG values.
The ability of Dmutant, two versions of I-Mutant 2.0,
MUpro, and PoPMuSiC to detect folding nuclei affected
by variations has been evaluated [34]. The dataset con-
tained 1409 variations from the ProTherm and some
methods were tested with the same data which they had
been trained. They used only correlation coefficients as
quality measures. The best being in the range of ~0.5.
The performance of structure-based stability preditors,
Dmutant, FoldX, and I-Mutant 2.0, were investigated with
data for two proteins. There were 279 rhodopsin and 54
bacteriorhodopsin variations [35]. The best prediction
accuracy for the rhodopsin dataset was <0.60, while it was
somewhat greater for the bacteriorhodopsin dataset.
Splice site predictors
mRNA maturation is a complex process, which may be
affected by variations in many steps. Prediction beha-
viour of nine systems, GenScan, GeneSplicer, Human
Splicing Finder (HSF), MaxEntScan, NNSplice, Splice-
Port, SplicePredictor, SpliceView and Sroogle was tested
[4].
The test dataset contained altogether 623 variations. The
first dataset contained 72 variations that affect the four
invariant positions of 5’ and 3’ splice sites. The second one
included 178 variations either localized at splice sites in
non-canonical positions, distant intronic variations, and
short distance variations. The third set of 288 exonic varia-
tions included 10 exonic substitutions that activate a cryp-
tic splice site. In the fourth dataset were negative controls,
altogether 85 variations without effect on splicing.
The results contain just the numbers of predicted
cases and the percentage of correct ones, thus detailed
analysis of the merits of the methods cannot be made.
The authors recommended some programs but stated
that the in silico predictions need to be validated
in vitro.
Checklist for method developers and users
This checklist is provided to help when comparing and
measuring performance of predictors and when selecting
a suitable one. These are items that method developers
should include in articles, or as supplement to articles,
as they enable effective comparison and evaluation of
the performance of predictors.
Items to check when estimating method performance
and comparing performance of different methods:
- Is the method described in detail?
- Have the developers used established databases and
benchmarks for training and testing (if available)?
- If not, are the datasets available?
- Is the version of the method mentioned (if several
versions exist)?
- Is the contingency table available?
- Have the developers reported all the six performance
measures: sensitivity, specificity, positive predictive
value, negative predictive value, accuracy and Matthews
correlation coefficient. If not, can they be calculated
from figures provided by developers?
- Has cross validation or some other partitioning
method been used in method testing?
- Are the training and test sets disjoint?
- Are the results in balance e.g. between sensitivity
and specificity?
- Has the ROC curve been drawn based on the entire
test set?
- Inspect the ROC curve and AUC.
- How does the method compare to others in all the
measures?
- Does the method provide probabilities for
predictions?
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